

Biomarker der kardiorenenalen Achse

Biomarkers of the Cardiorenal Axis

18.-19. January 2018

Multiplex-Proteomics
January 17, 2018



Deutsches Zentrum
für Herzinsuffizienz
Würzburg



Sehr geehrte Frau Kollegin,
sehr geehrter Herr Kollege,

die pathophysiologischen Verbindungen zwischen Erkrankungen des Herzens und der Niere rücken weiter in den Blickpunkt des wissenschaftlichen Interesses. Ihr Verständnis wird auf der konsequenten Anwendung systembiologischer Ansätze beruhen. Die Kooperation zwischen der Deutschen Diabetes Dialyse (4D) – Studie und die Ludwigshafen Risk and Cardiovascular Health (LURIC) Study bildet diese Entwicklungen ab. Auch noch mehr als 20 Jahre nach dem Beginn beider Studien ergeben sich viele wissenschaftliche Interaktionen zwischen den beteiligten Wissenschaftlern.

Die Tagung «Biomarker der kardiorenenalen Achse» wird es auch im Jahr 2018 zum Ziel haben, den neuesten Stand der Biomarker-Forschung an den Schnittstellen zwischen Kardiologie, Nephrologie, Labormedizin und angrenzenden Disziplinen zu behandeln.

Erstmals im Jahr 2018 bieten wir in Zusammenarbeit und mit Unterstützung der Firma Olink Proteomics, Uppsala, Schweden, am Mittwoch, den 17. Januar 2018, ein Satellitensymposium zum Thema Einsatz des Proximity Extension Assay (PEA) in der Biomarker Forschung an. Die Teilnehmerzahl dieser Veranstaltung ist begrenzt. Wir bitten daher um frühzeitige Anmeldung.

Wir hoffen, mit diesem Programm Ihr Interesse zu wecken und würden uns über viele Teilnehmer und gute Diskussionen freuen.

Prof. Dr. med. Christoph Wanner
Prof. Dr. med. Winfried März
Prof. Dr. med. Bernhard K. Krämer

Die Veranstaltung wurde bei der Landesärztekammer Bayern zur Zertifizierung angemeldet.

Dear Colleagues,

The pathophysiological links between diseases of the heart and the kidney stay in the focus of scientific interest. Our understanding of this interactions will be based on the consistent application of systems biology approaches. The cooperation between the German Diabetes Dialysis (4D) - Study and the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study reflects these developments. Still more than 20 years after initiation of both studies, many scientific interactions have evolved between the contributing scientists.

Also in 2018, the meeting „Biomarkers of Cardiorenal Axis“ is intended to display the state of the biomarker research at the interfaces between Cardiology, Nephrology and Laboratory Medicine and related disciplines.

For the first time in 2018 and in cooperation with the support of Olink Proteomics, Uppsala, Sweden, we will be offering a satellite symposium on addressing the use of the Proximity Extension Assay (PEA) in biomarker research on Wednesday, January 17, 2018. The number of participants in this event is limited. We therefore ask for early registration.

We hope to draw your interest with this program and would be excited about many many participants and good discussions.

Prof. Dr. med. Christoph Wanner
Prof. Dr. med. Winfried März
Prof. Dr. med. Bernhard K. Krämer

This event was submitted to the Medical Association for CME certification.

Program

Wednesday, January 17, 2018

Getting to the heart of the matter - targeted protein biomarker discovery for the advancement of precision medicine in cardiology and nephrology

11:15	Arrival, registration, coffee	14:10	Biomarker for cardiovascular precision medicine. Are we there yet? F. Zannad , Nancy
11:45	Lunch	14:40	Screening multiple biomarkers for associations with major cardiovascular events L. Wallentin, Uppsala
12:30	Opening and overview on the topics of the meeting A. Ballagi, Uppsala W. März, Mannheim	15:10	Title to be announced W. Koenig, Munich
12:40	Proximity extension assay and applications	15:30	Coffee break
12:40	Proximity Extension Assay (PEA) - A technology enabling targeted protein biomarker research Olink R&D, Uppsala	16:00	Biomarker discovery in cardiovascular and renal disorders
13:00	Prognostic biomarkers associated with cardiovascular Events in atrial fibrillation: Insights from the Aristotle Trial using Proximity Extension Assay (PEA)-technology Agneta Siegbahn, Uppsala	16:00	Proteomic analysis; insights from the Aurora trial P. Rossinol, Nancy
13:20	Plasma proteomics for epidemiology: combining antibody and mass spectrometry-based measurements M. Mayr, London	16:20	Experience from renal cohorts with CVD endpoints and preliminary results from urine analyses B. Fellström, Uppsala
13:50	Biomarkers reflecting tissue injury and repair in prediction of cardiovascular disease J. Nilsson, Lund	16:40	Plenary discussion Agneta Siegbahn, M. Mayr, J. Nilsson, P. Zannad, L. Wallentin, P. Rossinol, B. Fellström, W. Koenig
14:10	Epidemiological studies to advance precision medicine	17:40	Closing remarks A. Ballagi, Uppsala W. März, Mannheim
		17:50	End of the first day meeting
		19:30	Evening event: Wine tasting at the Residenz Würzburg

For further information on the proximity extension technique visit www.olink.com

Program

Thursday, January 18, 2018

9:00	Registration, coffee	15:00	Workshop I: Metabolism and Inflammation
9:30	Welcome and introduction into the topic of the meeting C. Wanner, Würzburg, W. März, Mannheim, B.K. Krämer, Mannheim		Chair: M. Herrmann, Graz
9:45	Perspectives Chair: P. Lansberg, Amsterdam	15:00	LDL cholesterol: really the culprit? R. Laaksonen, Tampere
9:45	Translating clinical trials into patient care T. Wierzbicki, London	15:25	Lipoproteins and inflammation T. Speer, Homburg
10:15	EMPA-REG Outcome: Nephroprotection through SLGT2 inhibition C. Wanner, Würzburg	15:50	Lipid-lowering by diet: Hard facts, pious wishes? S. Lorkowski, Jena
10:45	New opportunities and obstacles for biomarker based decision support in cardiovascular care L. Wallentin, Uppsala	16:15	Afamin is associated with prevalent and incident type 2 diabetes in the general population and predictive for gestational diabetes in pregnancy H. Dieplinger
11:15	Coffee Break	15:00	Workshop II: Biomarkers of kidney disease Chair: H.J. Anders, Munich
11:30	Genomics Chair: Hans Dieplinger, Innsbruck	15:00	Does iron deficiency affect the interaction between FGF-23 and cardiovascular disease? G. Heine, Homburg
11:30	Novel drug targets arising from genome-wide association studies H. Schunkert, Munich	15:25	The role of vitamin K in vascular calcification V. Brandenburg, Aachen
12:00	TBD K. Stefansson, Reykjavic	15:50	The Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa) Study F. Hammer, Würzburg
12:30	Recent developments in Mendelian randomization studies in the age of large-scale accessible genomics data J. Zheng, Bristol	16:15	Tubular Dickkopf-3 and the development of renal atrophy and fibrosis D. Fliser, Homburg
13:00	Lunch Break	16:40	Coffee Break
13:30	Guided Poster Discussion Chair: B. Fellström, Uppsala, E. Windler, Hamburg		

Program

Thursday, January 18, 2018

17:00	Workshop III: Biomarkers of Heart Disease Chair: J. Scherberich, Munich
17:00	Inflammatory cells in heart disease A. Zirlik, Freiburg
17:25	Gut microbiota and vascular disease N. Marx, Aachen
17:50	Serum Uromodulin and cardiovascular mortality M. Kleber, Mannheim
18:15	Lipoprotein analysis by nuclear magnetic resonance spectroscopy P. Pagel, Regensburg
17:00	Workshop IV: Biomarkers of Kidney Disease Chair: A. Ritsch, Innsbruck
17:00	Novel mechanisms of vascular calcification and clinical implications J. Völk, Berlin
17:25	SuPAR in clinical cohorts Claudia Sommerer, Heidelberg
17:50	Parameters of calcium and phosphate metabolism in cardiac surgical patients – Risk markers of clinical outcome A. Zittermann, Bad Oeyenhausen
18:15	„Proteasuria – a novel mechanism of edema development in the nephrotic syndrome F. Artunc, Tübingen
18:35	End of the second day
20:00	Get together

Friday, January 19, 2017

8:30	Clinical Trials Chair: B. Fellström, Uppsala
8:30	Translational science: From biology to therapeutics U. Fraass, Munich
9:00	PCSK9 – Update U. Laufs, Leipzig
9:30	CANTOS: Canakinumab for everyone ? W. König, München
10:00	Coffee Break
10:15	Renocardial markers Chair: W. Herrmann, Homburg
10:15	Carbamylated albumin – update 2018 A. Berg, Boston
10:45	Circulating permeability factor suPAR: From concept to clinic J. Reiser, Chicago
11:15	Omega 3 index and blood pressure – a causal relationship? C. von Schacky, Munich
11:45	Vitamin D: still hot? S. Pilz, Graz
12:15	Wrap up C. Wanner, Würzburg, W. März, Mannheim, B.K. Krämer, Mannheim
12:30	Lunch and farewell

Poster Presentations

Prognostic value of Cathepsin S in the 4D trial

[H..J. Anders et al., Munich](#)

Prognostic significance of hemodynamic parameters in hemodialysis patients

[F. Artunc et al., Tübingen](#)

Effect of spironolactone on vascular function in patients on hemodialysis

[S. Bausch et al., Würzburg](#)

A critical update on solarium use and risk for malignant melanoma: meta-analysis and evidence-based systematic review

[B. Burgard et al., Homburg](#)

Testosterone in dialysis patients

[J.J. Carrero et al., Würzburg](#)

Effect of the MoKaRi diet on the plasma lipidome

[Christine Dawczynski et al., Jena](#)

The association of INR with mortality in patients referred for coronary angiography

[Graciela Delgado et al., Mannheim](#)

Clinical benefit of a short term dietary oatmeal intervention in patients with type 2 diabetes mellitus and severe insulin resistance: A cross-over study

[Graciela Delagodo et al., Mannheim](#)

The diagnostic value of high sensitivity troponin in dialysis patients

[Christane Drechsler et al., Würzburg](#)

Lipoprotein (a) in the DETECT study

[A. Dressel et al., Mannheim](#)

Health economic evaluation of PCSK9-Inhibition

[A. Dressel et al., Mannheim](#)

Non-oxidised PTH and clinical outcomes in patients with coronary artery disease

[T. Dschietzig, Berlin and Bensheim](#)

Neprilysin in CKD

[I. Emrich, Homburg](#)

Beta trace protein and mortality

[D. Enko et al., Steyr](#)

Prevalence of familial hypercholesterolemia in the DEGS study

[F. Fath et al., Mannheim](#)

H-ALERT: An approach to decision support in primary care

[F. Fath et al., Mannheim](#)

The aldosterone to renin ratio in the clinical laboratory

[T. Fenyvesi et al., Weiden](#)

Prevalence and determinants of vitamin D deficiency in Germany

[T. Fenyvesi et al., Weiden](#)

ODIN: Mendelian randomization of vitamin D and mortality

[M. Gaksch et al., Graz](#)

Effects of vitamin D supplementation on its metabolism in vitamin D insufficient adults

[M. Gaksch et al., Graz](#)

Development of a scoring system for predicting the efficacy of statin treatment in patients on hemodialysis

[B. Genser et al., Vienna](#)

Poster Presentations

Time on hemodialysis and clinical efficacy of statins in the 4D study

B. Genser et al., Vienna

Systems biology approaches to risk prediction

Ingrid Gergei et al., Mannheim

Genome wide association study of klotho

Ingrid Gergei et al., Mannheim

Galektin 3 – binding protein and CD163 interaction

C. Gleissner et al., Heidelberg

Assessment of the heart age using the Coropredict multimarker panel

Tanja Grammer et al., Mannheim

Left ventricular hypertrophy measured by MRI, echocardiography and ECG in patients on hemodialysis

S. Grebe et al., Würzburg

Galectin 3 – interaction with renin-angiotensin system

M. Grübler et al., Bern

7-DHC and mortality in the LURIC study

M. Grübler et al., Bern

“Fass Dir ein Herz”: the Austrian registry for familial hypercholesterolemia

Gabriele Hanauer-Mader et al., Vienna

Mineralocorticoid hormone antagonism and its metabolic consequences in hemodialysis patients

T. Hauser et al., Würzburg

Cellular cholesterol efflux in participants of the Young Fins Study

Monika Hunjadi et al., Innsbruck

A case of glycerol kinase deficiency with pseudohypertriglyceridemia

Christel König, G. Klose et al., Bremen

Prevalence of familial hypercholesterolemia in the LURIC study estimated by the CARRENAL custom designed microarray

Kleber et al., Mannheim

Saturated fatty acids and mortality

M. Kleber et al., Mannheim

Genome wide association study of homoarginine using the HRC reference panel

M. Kleber et al., Mannheim

Vascular adhesion molecules and severe obesity – a subgroup analysis of the LURIC study

M. Kleber et al., Mannheim

Mortality prediction in stable hemodialysis patients with YKL-40

G. Lorenz et al. Munich

The NutriCARD cluster

S. Lorkowski et al., Jena

Measurement of vitamin D metabolites by mass spectroscopy

S. Zelzer et al., Graz

Thyroid function and vitamin D

A. Merke et al., Bensheim

Vitamin D in the DETECT study

A. Merke et al., Bensheim

Thyroid metabolism and low density lipoproteins

A. Merke et al., Bensheim

Poster Presentations

Regional purchasing power and mortality in the Rhine-Neckar Region

[Angela Moissl et al., Mannheim](#)

Homoarginine - a prognostic indicator in adolescents and adults with complex congenital heart disease?

[Tanja M. Raedle-Hurst, Homburg](#)

Telomer length and mortality in the LURIC study

[Irene Pusceddu et al., Bozen](#)

Variants of genes involved in skin pigmentation are associated with vitamin D concentrations

[R. Saternus et al., Homburg](#)

Comparison of contemporary methods to measure lipoprotein (a)

[H. Scharnagl et al., Graz](#)

Effects of PCSK9 inhibition on lipoprotein fractions and circulating PCSK9

[H. Scharnagl et al., Berlin](#)

Genetics of patients with clinical suspicion of familial hypercholesterolemia of a lipidology specialty outpatients unit

[Ulrike Schatz et al., Dresden](#)

Apolipoprotein C3 and mortality in the LURIC study

[G. Silbernagel et al., Graz](#)

NMR resolves HDL subfractions with differential effects on mortality

[G. Silbernagel et al., Graz](#)

LDL triglycerides, but not LDL cholesterol predict mortality in the LURIC study

[G. Silbernagel et al., Graz](#)

Cascade Screening and Registry for High Cholesterol (CaRe-High): interim results

[Nina Schmidt, Ulrike Schatz et al., Mannheim](#)

Role of vitamin D deficiency in chronic obstructive pulmonary disease - an overview

[R. Siekmeier et al., Bonn](#)

Role of vitamin D deficiency in asthma bronchiale - an overview

[R. Siekmeier et al., Bonn](#)

Monitoring of the NFAT regulated gene expression in NTX patients treated with tacrolimus

[Claudia Sommerer et al., Heidelberg](#)

Hepcidin and mortality in the LURIC study

[P. Strnad et al., Aachen](#)

Characteristics of long-term survivors in 4D

[S. Triebvetter et al., Würzburg](#)

Effects of vitamin D supplementation on FGF23: a randomized-controlled trial

[C. Trummer et al., Graz](#)

Phosphate meets uromodulin

[J. Scherberich et al., Munich](#)

Effect of Vitamin D supplementation on the RAAS system in end-stage heart failure patients

[A. Zittermann et al., Bad Oeyenhausen](#)

ADMA und MPO: Is there an interaction?

[Sieglinde Zelzer et al., Graz](#)

Poster Presentations

Effects of declining renal function and possible thresholds of renal function on plasma malondialdehyde and myeloperoxidase concentrations from the BIOC-LAIMS Study

Sieglinde Zelzer et al., Graz

Link between myeloperoxidase, asymmetric dimethylarginine and the renin-angiotensin-aldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study Lipoprotein (a) and long-term prognosis in the LURIC study

Sieglinde Zelzer et al., Graz

Lipoprotein (a) and long-term prognosis in the LURIC study

S. Zewinger et al., Homburg Saar



LOGISTICS

Logistics

Biomarkers of the cardiorenal axis

MEETING VENUE

Deutsches Zentrum für Herzinsuffizienz
Universitätsklinik Würzburg
Am Schwarzenberg 15, Haus A15
97078 Würzburg

MEETING TIMES

Wednesday, January 17, 2018
12:30 – 17:50

Thursday, January 18, 2018
9:00 – 18:35

Friday, January 19, 2018
8:30 – 12:30

ORGANIZERS

D-A-CH-Gesellschaft Prävention von
Herz-Kreislauf-Erkrankungen e. V.
Schulterblatt 120
c/o MasterMedia GmbH
20357 Hamburg

Medizinische Klinik V
Universitätsmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim

SYNLAB Akademie für Ärztliche Fortbildung
SYNLAB Holding Deutschland GmbH
P5,7
68161 Mannheim

ADDITIONAL POSTERS AND INFORMATION

Do you wish to contribute a poster?
Do you need other information?

PLEASE CONTACT

Prof. Dr. med. Christoph Wanner

Universitätsklinikum Würzburg
Medizinische Klinik und Poliklinik I
Abteilung Nephrologie

Oberdürrbacher Straße 6
97080 Würzburg

Telefon +49 931 201-39030
Telefax +49 621 201-639030
E-Mail Wanner_C@ukw.de

Prof. Dr. med. Bernhard K. Krämer

Medizinische Klinik V
Universitätsmedizin Mannheim

Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Telefon +49 621 383-5172
Telefax +49 621 383-3804
E-Mail bernhard.kraemer@umm.de

Univ.-Prof. Dr. med. Winfried März

SYNLAB Akademie für Ärztliche Fortbildung
SYNLAB Holding Deutschland GmbH

P5,7
68161 Mannheim


Telefon +49 621 43179-432
Telefax +49 621 43179-433
E-Mail winfried.maerz@synlab.com

Logistics

Biomarkers of the cardiorenal axis

LOCATION

Deutsches Zentrum für Herzinsuffizienz
Universitätsklinikum Würzburg
Am Schwarzenberg 15, Haus A15
97078 Würzburg



SPONSORS

Sponsors

Biomarkers of the cardiorenal axis

MAIN SPONSOR

AMGEN GmbH
Munich 16.000 Euro



Immundiagnostik AG
500 Euro



SPONSORS

Abbott GmbH & Co. KG
1.000 Euro



Lilly Deutschland GmbH
2.000 Euro



Alexion Pharma Germany GmbH
1.000 Euro



MSD Sharp & Dohme GmbH
1.000 Euro



Axon Lab AG
1.500 Euro



numares AG
1.000 Euro



BASF – The Chemical Company
1.000 Euro



Ocupharm GmbH
1.000 Euro

Ocupharm GmbH

Bayer Vital GmbH
1.500 Euro



Olink Proteomics
10.000 Euro



bestbion dx GmbH
500 Euro



Sanofi-Aventis Deutschland GmbH
4.000 Euro



Boehringer Ingelheim Pharma GmbH & Co. KG
4.000 Euro



Shire Deutschland GmbH
1.000 Euro



DiaSorin Deutschland GmbH
1.000 Euro



Siemens Healthcare Diagnostics GmbH
1.000 Euro



Registration

Biomarkers of the cardiorenal axis

Please issue your binding registration by 22.12.2018 latest to www.synlab.com/de/mensch/fortbildung, by e-mail to manuela.hormuth@synlab.com or winfried.maerz@synlab.com or by fax to **+49 (0)621 43179-433**.

CONTACT

SYNLAB Akademie für Ärztliche Fortbildung
SYNLAB Holding Deutschland GmbH
P5, 7
68161 Mannheim

Telefon +49 (0)621 43179-432
Telefax +49 (0)621 43179-433
E-Mail manuela.hormuth@synlab.com
winfried.maerz@synlab.com

We kindly ask you for binding registration, as non-attendance will generate avoidable costs for the organizers.

TEILNAHME SYMPOSIEN

I will participate with ____ person(s) on the following days

- ☐ ____ person(s) on 17.01.2018
☐ ____ person(s) on 18.01.2018
☐ ____ persons on 19.01.2018

TEILNAHME ABENDVERANSTALTUNG

- ☐ Olink – 17.01.2018 *only possible upon participation in the Olink satellite meeting*
☐ Get together – 18.01.2018

HOTELÜBERNACHTUNG

Number of nights ____

- ☐ Arrival 16.01.2018
☐ Arrival 17.01.2018
☐ Arrival 18.01.2018

Please provide information completely and clearly

Address

Telephone and fax

E-mail

Participant name(s)

Date, signature, and stamp

Notes

A large rectangular area filled with a uniform grid of small, light gray dots, intended for handwritten notes. The grid consists of 20 columns and 30 rows of dots.

Experience the power of **Atellica**



Atellica™ Solution*

Flexible, scalable, automation-ready immunoassay and chemistry analyzers.

A new diagnostics portfolio engineered to deliver control and simplicity so you can drive better outcomes.

Atellica™ COAG 360 System†

Fully automated high-volume specialty coagulation system that unifies five testing methodologies.

Atellica™ PM 1.0 Software*

Process management software to optimize lab operations through data analytics and visualization.

Atellica™ 1500 Automated Urinalysis System†

Fully automated, streamlined urine chemistry and sediment analyzers.

Atellica™ NEPH 630 System†

Mid-volume, dedicated nephelometric system to further simplify specialty protein testing.

Atellica™ MDX 160 Molecular System‡

Flexible, automated molecular system with maximum productivity for multiple sample types.

*Product availability will vary by country.

†Not available for sale in the U.S. Product availability will vary by country.

‡Under development. Not available for sale. Product availability will vary by country.

Atellica is a trademark of Siemens Healthcare Diagnostics Inc.

A91DX-9563-A2-4A00. © Siemens Healthcare Diagnostics Inc., 2017